$45 billion for Genentech
Tuesday, 22 July, 2008
Swiss pharma giant Roche has offered to buy out the remaining 44 per cent of shares in US biotech Genentech for US$43.7 billion (A$45 billion).
Roche acquired a majority in Genentech in 1990 and currently owns 55.9 per cent of the San Francisco company, set up by biotech pioneer Herb Boyer in 1976. Genentech manufactures the blockbuster cancer drugs Herceptin and Avastin, among others.
Roche is offering US$89 per share in cash and is promising to respect Genentech's 'unique research culture' and headquarters.
Roche estimates that the combined entity will be the seventh largest US pharmaceuticals company in terms of market share and will generate more than US$15 billion in annual revenues.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
